Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Excedrin Migraine Full Migraine Indication Approved By FDA

This article was originally published in The Tan Sheet

Executive Summary

Bristol-Myers Squibb's Excedrin Migraine indication for full migraine syndrome was approved by FDA Oct. 7. The new labeling simply bears the indication "Treats migraine."

You may also be interested in...



Advil Migraine Liqui-Gels Join Growing Category, Stress Distinctiveness

Upcoming marketing efforts accompanying the introduction of Whitehall-Robins' Advil Migraine Liqui-Gels likely will attempt to differentiate the product from its migraine-specific competitors by emphasizing the analgesic's speedy delivery form.

Advil Migraine Liqui-Gels Join Growing Category, Stress Distinctiveness

Upcoming marketing efforts accompanying the introduction of Whitehall-Robins' Advil Migraine Liqui-Gels likely will attempt to differentiate the product from its migraine-specific competitors by emphasizing the analgesic's speedy delivery form.

Advil Migraine Liqui-Gels Join Growing Category, Stress Distinctiveness

Upcoming marketing efforts accompanying the introduction of Whitehall-Robins' Advil Migraine Liqui-Gels likely will attempt to differentiate the product from its migraine-specific competitors by emphasizing the analgesic's speedy delivery form.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090407

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel